Idorsia is made up of exclusivity restrictions on

Ad -hoc announcement according to art. 53 LR

Allschwil, Switzerland – February 26, 2025
Idorsia Ltd (six: idia) announced today that the exclusivity agreement signed in November 2024 was concluded with a non -mentioned party for the global rights to aprocitan, without the party being signed as foreseen in the non -binding semester sheet. Idorsia will keep the exclusivity fee of USD 35 million in December 2024.

André C. Müller, CEO of Idorsia, commented:
“It is disappointing that the party that has not been mentioned has decided not to sign the deal intended for aphitan, although he shares our view of the quality of the financial value. We have to continue and will resume discussions with other potential partners who recognize the blockbuster potential of aphitan in uncontrolled high blood pressure, especially in patients with chronic kidney disease and high blood pressure. “

Notes to the publisher

About aprocitan
Apocitan is the once daily, oral, double endotheline receptor antagonist with two endotheline receptors that inhibits the binding of ET-1 to ETA and ETB receptors. Apocitan has been approved in the USA as Tryvio ™ for the treatment of systemic hypertension in combination with other antihypertensive and has been available in stores in Calla and Switzerland since October 2024.

About Idorsia
Idorsia Ltd turns for more – we have more passion for science, we see more options and we want to help more patients.

The purpose of Idorsia is to question accepted medical paradigms and to answer the questions that are most important. To achieve this, we will develop transformative pharmaceutical geders with internal skills or together with partners discovering, developing and commerce and idorsia into a leading biopharmaceutical company with a strong scientific core.

Idorsia has its headquarters near Basel, Switzerland – A European Biotech -Hub – Idorsia has a very experienced team of committed specialists that covers all disciplines from bank to bed. Quviviq ™ (Daridorexant), a different kind of insomnia with the potential to revolutionize this increasing concern of public health; Strong partners to maximize the value of our portfolio; a promising internal development pipeline; And a specialized engine for drug discoveries that focus on small medication with small molecules that the treatment paradigm can change for many patients.

Idorsia is listed on the Six Swiss Exchange (ticker symbol: idia).

For more information, please contact
Investor and media relationships
Idorsia Pharmaceuticals LTD, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “future -oriented statements” that relate to the company of the company, which can be identified by the use of future -oriented terminology such as “estimates”, “faith”, “expected”, “May”, “are”. expected that “,” wants “,” will continue “,” should “,” “,” search “,” pending “or” anticipated “or similar expressions or through discussion about strategy, plans or intentions. Descriptions of the company's investment and research and development programs as well as expected expenditure in connection, the descriptions of new products that are introduced by the company, and expected the customer issue for such products and Products in the company's existing portfolio. , Distinguish services or achievements that can be expressed or implied by such future -oriented statements. or if the underlying assumptions prove to be wrong, the actual results can vary significantly from those described here as expected, valued or expected, described here.